Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study

(2014) J. R. Strosberg et al.   ONCOLOGIST

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

(2012) Ulrich-Frank Pape et al.   NEUROENDOCRINOLOGY

Evaluating the Characteristics and the Management of Patients With Neuroendocrine Tumors Receiving Octreotide LAR During a 6-Year Period

(2011) Lowell Anthony et al.   PANCREAS

Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease

(2010) Irvin M. Modlin et al.   ANNALS OF SURGICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

(2009) Dermot O’Toole et al.   NEUROENDOCRINOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY